Misplaced Pages

Özlem Türeci

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by J at BioNTech (talk | contribs) at 07:59, 6 January 2021 (updated/expanded; disclosure: this edit is made on behalf of BioNTech; please check talk page for full COI disclosure.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 07:59, 6 January 2021 by J at BioNTech (talk | contribs) (updated/expanded; disclosure: this edit is made on behalf of BioNTech; please check talk page for full COI disclosure.)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

Özlem Türeci
Uğur Şahin in 2020
Born (1967-03-06) March 6, 1967 (age 57)
Lastrup, Germany
CitizenshipGermany
Alma mater
Occupations
  • Chief Medical Officer
  • Chief Executive Officer
  • Company Founder
Years active1992–present
Employers
Organizations
  • American Society of Clinical Oncology
  • American Association for Cancer Resarch
  • German Society for Immunology
  • German Society for Hematology and Oncology
Known for
OfficeCMO BioNTech SE
Term2018–present
Spouse Uğur Şahin ​(m. 2002)​
Awards
  • Calogero Pagliarello Research Award
  • Georges Köhler Prize
  • German Sustainability Award
  • Axel Springer Award
WebsiteProfile at BioNTech

Özlem Türeci (born March 6, 1967 in Lastrup) is a German physician, scientist and entrepreneur. She was the founder of the publicly traded company BioNTech in 2008, which developed a messenger RNA-based vaccine against COVID-19 in 2020. Türeci has served as BioNTech's chief medical officer since 2018. She was founder and CEO of Ganymed Pharmaceuticals from 2008 to 2016. She is also a private lecturer at Johannes Gutenberg University in Mainz, Germany.

Life and education

Özlem Türeci is the daughter of a Turkish surgeon who worked at the Catholic hospital St. Elisabeth-Stift in Lastrup in the district of Cloppenburg. She attended, among others, the Städtisches Gymnasium in Bad Driburg and the Werner-von-Siemens-Gymnasium in Bad Harzburg. She studied human medicine at Saarland University in Homburg and received her doctorate from the Medical Faculty of Saarland in 1992. She was a habilitation and Heisenberg fellow of the German Research Foundation. Her research focuses on the identification and characterization of tumor-specific molecules and the development of immunotherapies against cancer. In 2002, she completed her habilitation at the Johannes Gutenberg University in Mainz in the field of molecular medicine.

Türeci met her future husband Uğur Şahin while he was working at Saarland University Hospital in Homburg, where she was completing her final year of studies. In 2002, the couple married and have a daughter together.

Career

Türeci co-founded and has served as Chair of the German Top Research Cluster for Individualized Immune Intervention Ci3 of the German Federal Ministry of Education and Research since 2011 and President of the Association for Cancer Immunotherapy (CIMT), the largest European association for cancer immunotherapy, since 2019. She is internationally active as a lecturer.

University Medicine Mainz

Türeci was a staff member of the University Medical Center Mainz [de] in the special research area Immunology there. Since 2002, she has been a private lecturer at the University Medical Center Mainz in the field of cancer immunotherapy. Together with her husband Ugur Sahin and her mentor Christoph Huber, they developed the concept of a "translational institute", which was realized in 2001 with the foundation of TRON. This is a biopharmaceutical research institute that develops new diagnostics and drugs for the therapy of cancer and other diseases with high unmet medical needs.

Ganymed Pharmaceuticals

Türeci founded the company Ganymed Pharmaceuticals in 2001 with her later husband Uğur Şahin. Ganymed and also BioNTech, which was founded later, are spin-offs of the Johannes Gutenberg University Mainz. This company developed the monoclonal antibody zolbetuximab, which is to be used against esophageal and gastric cancer. She led the company from 2008 to 2016 in the role of Chief Executive Officer (CEO) until the acquisition. Prior to that, she was chief scientific officer (CSO) from 2001 to 2008. In 2016, the company was sold to Astellas Pharma and is now a subsidiary.

Biontech

Headquarters of BioNTech in Mainz

In 2008, Türeci was one of the founders of the Mainz-based biotechnology company BioNTech, of which she has been Chief Medical Officer (CMO) since 2018. From 2009 to 2018, she served as chair of the company's scientific advisory board. BioNTech is focused on the development and manufacturing of active immunotherapies for a patient-specific approach to the treatment of cancer and other serious diseases. As CMO, she is primarily responsible for Clinical Research and Development. BioNTech has been conducting research on a vaccine against the infectious disease COVID-19 since January 2020 under the leadership of Özlem Türeci and her husband Uğur Şahin, who is the company's CEO, making her responsible for the clinical trials area in the development of the vaccine BNT162b2 (also known as Comirnaty). Türeci is involved in more than 500 patents filed with her company and partners.

Memberships

Türeci is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Resarch (AACR), the German Society of Immunology [de], and the German Society of Hematology and Oncology [de].

Awards

See also

References

  1. "Das Führungsteam", Homepage (in German), BioNTech, retrieved November 30, 2020
  2. Vorlesungsverzeichnis, Johannes Gutenberg Universität Mainz, retrieved November 30, 2020
  3. "Privatdozentin Dr. Özlem Türeci", DFG - GEPRIS - (in German), Deutsche Forschungsgemeinschaft, retrieved November 30, 2020
  4. Lastruperin ist Corona-Hoffnung: Biontech-Gründerin Türeci (in German), NDR, retrieved November 30, 2020
  5. Budde, Reinhold, Forscherin lebte in Bad Driburg (in German), retrieved November 30, 2020
  6. Türeci, Özlem, Nachweis von DNA-Polymorphismen anhand von Minisatelliten-Profilen bei Tumoren und Zellinien und Untersuchungen zur Caseinkinase 2 in der Oozyte von Xenopus laevis, retrieved December 24, 2020
  7. "Werte schaffen durch Innovation" (PDF), Natur & Geist-Das Forschungsmagazin der Johannes Gutenberg-Universität Mainz, retrieved November 30, 2020
  8. Stolzenberg, Tobias (2018), "Zwei gegen den Krebs", Technology Review (in German), vol. 5, Hannover: Heise Verlag, retrieved October 26, 2020
  9. Läsker, Kristina (January 14, 2009), "Die Krebsforscherin", Süddeutsche Zeitung / Ausgabe München (in German), p. 18, retrieved October 26, 2020
  10. BMBF LS5 Internetredaktion, Cluster für Individualisierte ImmunIntervention (Ci3) - BMBF Spitzencluster (in German), retrieved November 30, 2020{{citation}}: CS1 maint: numeric names: authors list (link)
  11. Chairpersons – Cluster for Individualized Immune Intervention (Ci3) e.V., retrieved November 30, 2020
  12. Who We Are, Association for Cancer Immunotherapy CIMT, retrieved November 30, 2020
  13. "SPEAKERS", Science Asia Conference, retrieved November 30, 2020
  14. "AG Sahin/Türeci", 14. Mainzer Sommer Uni, III. Medizinische Klinik und Poliklinik der Johannes Gutenberg-Universität Mainz, retrieved November 30, 2020
  15. Priv.-Doz. Dr. med. Özlem Türeci, Internistin in 55131 Mainz, Obere Zahlbacher Straße 63 (in German), retrieved November 30, 2020
  16. Rodríguez Fernández, Clara (October 9, 2017), The Woman Developing the Next Generation of Cancer Immunotherapy, retrieved November 30, 2020
  17. Festakt zum Jubiläum der Uni Mainz (in German), retrieved November 30, 2020
  18. Über TRON (in German), TRON – Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz, retrieved October 26, 2020
  19. Miller, Joe (March 20, 2020), "Ugur Sahin: The Immunologist Racing To Find a Vaccine", Financial Times, retrieved October 26, 2020
  20. Erfolgreiches „Mainzer Modell“ (in German), March 26, 2015, retrieved November 30, 2020
  21. Stolzenberg, Tobias (October 8, 2018), "Zwei gegen den Krebs", Heise Online (in German), retrieved October 26, 2020
  22. "Astellas kauft Ganymed", Transkript (in German), October 28, 2016, retrieved October 26, 2020
  23. Form 20-F, U.S. Securities and Exchange Commission, March 31, 2020, retrieved November 10, 2020
  24. Hofmann, Siegfried; Terpitz, Katrin (March 16, 2016), "Impfung gegen Krebs", Handelsblatt (in German), p. 16
  25. Biontech: Mit Lichtgeschwindigkeit zum ersten Corona-Impfstoff (in German), Deutsche Welle (DW), November 9, 2020, retrieved November 30, 2020
  26. Hofmann, Siegfried; Wermke, Christian (April 23, 2020), "Ugur Sahin und Özlem Türeci: Dieses Medizinerpaar entwickelt einen Covid-19-Impfstoff.", Handelsblatt (in German), retrieved October 26, 2020
  27. "The Husband-and-Wife Team Behind the Leading Vaccine to Solve Covid-19", The New York Times, November 10, 2020, retrieved November 17, 2020
  28. Özlem Türeci's research while affiliated with Helmholtz Institut Mainz and other places, ResearchGate, retrieved November 30, 2020
  29. Preisträger Vincenz-Czerny-Preis und deren Arbeiten (in German), Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie, retrieved October 26, 2020
  30. Ugur Sahin, Managing Director (Science and Research) of Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz – Tron, University of Birmingham, retrieved October 26, 2020
  31. "Erfolgreiche Suche nach Tumormarkern", Ärzte Zeitung (in German), Springer Medizin, October 13, 2005, retrieved October 26, 2020
  32. Koehler-Preis (in German), Deutsche Gesellschaft für Immunologie, retrieved October 26, 2020
  33. "Deutscher Nachhaltigkeitspreis: Startseite", Deutscher Nachhaltigkeitspreis (in German), retrieved December 17, 2020
  34. Miller, Joe; Cookson, Clive (December 16, 2020), "FT People of the Year: BioNTech's Ugur Sahin and Ozlem Tureci", Financial Times, retrieved December 17, 2020
  35. "Axel Springer Award 2021 geht an Biontech-Gründer", Die Welt, December 23, 2020, retrieved December 23, 2020

Further reading

External links

Scholia has an author profile for Özlem Türeci. Categories: